Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
Key Financial Performance
Record Quarterly Net Revenue $209.4 million, a 31% increase year-over-year, driven by strong performance from Jornay PM and the pain portfolio.
Adjusted EBITDA $133 million, a 27% increase year-over-year, reflecting robust operational performance.
Jornay PM Net Revenue $41.8 million, a 46% growth year-over-year, attributed to increased prescriptions (up 20%) and expanded commercial efforts.
Pain Portfolio Net Revenue $167.6 million, an 11% increase year-over-year, driven by strong demand and durability of the portfolio.
Cash from Operations $78.4 million, reflecting strong cash generation capabilities.
Debt Repayment $16.1 million repaid, contributing to a strengthened balance sheet.
Cash Balance $285.9 million at the end of the quarter, showcasing financial stability.
Belbuca Net Revenue $58.3 million, a 10% increase year-over-year, driven by strong brand fundamentals.
Xtampza ER Net Revenue $50.5 million, a 2% increase year-over-year, supported by its abuse-deterrent technology.
Nucynta Franchise Net Revenue $54.8 million, a 21% increase year-over-year, primarily due to profitability improvements and rebate settlements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Jornay PM prescription growth: Jornay PM prescriptions grew 20% year-over-year, generating a record $41.8 million in net revenue. The product is the fastest-growing stimulant for ADHD, with a 14% increase in weekly prescriptions during the back-to-school season.
Pain portfolio revenue: Net revenue from the pain portfolio reached a record $167.6 million, up 11% year-over-year. This includes growth across all three core pain medicines.
Market share for Jornay PM: Jornay PM's market share in the long-acting branded methylphenidate market grew to 23.4%, up 6.3 percentage points year-over-year.
Prescriber base for Jornay PM: The prescriber base for Jornay PM reached an all-time high of 27,700, up 22% year-over-year.
Financial performance: Record quarterly net revenue of $209.4 million, up 31% year-over-year, and record adjusted EBITDA of $133 million, up 27% year-over-year. Cash from operations was $78.4 million, and $16.1 million of debt was repaid.
Capital deployment: The company repurchased $25 million in shares year-to-date and repaid $16.1 million in debt during the quarter. It ended the quarter with $285.9 million in cash.
Expansion into new therapeutic area: Successfully integrated Jornay PM into the portfolio and made strategic investments to drive its growth.
Business development: Actively pursuing additional differentiated medicines to expand the portfolio and drive long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Potential challenges in maintaining the growth trajectory of Jornay PM and the pain portfolio amidst competitive pressures and market dynamics.
Regulatory Hurdles: No explicit mention of regulatory challenges, but the company operates in a highly regulated pharmaceutical industry, which inherently carries risks.
Supply Chain Disruptions: No explicit mention of supply chain issues, but the pharmaceutical industry is generally vulnerable to such risks.
Economic Uncertainties: No explicit mention of economic uncertainties, but macroeconomic factors could impact consumer spending and healthcare budgets.
Strategic Execution Risks: The company is heavily reliant on the success of Jornay PM and its pain portfolio. Any failure in strategic execution, such as marketing campaigns or sales force expansion, could adversely impact growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Financial Guidance: The company has raised its 2025 financial guidance, expecting total product revenues in the range of $775 million to $785 million, representing a 24% increase year-over-year. Adjusted EBITDA is projected to be between $460 million and $470 million, a 16% increase year-over-year. Adjusted operating expenses are expected to range from $235 million to $240 million, reflecting targeted investments to support Jornay's growth and future momentum.
Jornay PM Revenue Projections: Jornay PM revenue is expected to be in the range of $145 million to $150 million, representing 46% growth from 2024 pro forma revenue. Gross to net improvements are anticipated, with full-year gross to net expected to be in the mid-60% range.
Pain Portfolio Outlook: The pain portfolio is expected to continue providing a durable financial base for growth and diversification. The company anticipates maximizing revenues from the portfolio in 2026 and beyond through demand generation and profitability enhancements. No major payer changes are expected in 2026, and Xtampza ER has secured exclusive formulary access for approximately 1.7 million commercial lives starting January 1, 2026.
Capital Deployment Strategy: The company remains committed to disciplined capital deployment, balancing business expansion, share repurchases, and debt repayment. Year-to-date, $25 million has been returned to shareholders through share repurchases, with $150 million remaining in the current Board-authorized program through December 31, 2026. Net leverage is expected to be less than 1x by year-end 2025.
Market Trends and Strategic Plans: The company plans to continue raising awareness and adoption of Jornay PM among prescribers, caregivers, and patients, leveraging expanded sales force and marketing campaigns. It also aims to further grow its differentiated pain portfolio and actively pursue business development opportunities to expand and diversify its portfolio.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company has strategically deployed capital through share repurchases. Year-to-date, $25 million of value has been returned to shareholders through an accelerated share repurchase program. Additionally, there is $150 million remaining in the current Board-authorized share repurchase program, which can be leveraged opportunistically through December 31, 2026.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:For Q3, how did return reserves and inventory impact script growth, and what was the effect of gross to net improvements?
A:Colleen Tupper explained that gross to net improved in Q3 compared to the first half of the year, with Q1 at 70%, Q2 at 67%, and Q3 at 62%. The improvement was driven by seasonality, better return rates, and favorable contracting.
Q:Did the expanded sales force have a major impact on Q3, or should we expect more acceleration in Q4 and 2026?
A:Scott Dreyer stated that there was no significant impact in Q3 from the expanded sales force. Early signals of impact were observed, such as reaching more customers and expanding the target universe from 17,000 to 21,000 targets, with 3,800 writing prescriptions. Most impact is expected in 2026 and beyond.
Q:Can you explain the inventory movements and net price tailwinds for Jornay in the back half of the year, and whether this dynamic will persist in 2026?
A:Colleen Tupper noted that inventory for controlled substances averages around 15 days on hand, with Jornay at 17 days in Q3. Gross to net improvements were due to better return rates and contracting. Seasonal patterns will continue to affect gross to net, with full-year rates expected to stabilize in the mid-60% range.
Q:How has the adherence rate for Jornay been trending since the back-to-school season?
A:Scott Dreyer mentioned that adherence rates for Jornay PM are consistent with other ADHD medications, showing a typical adherence curve of 9 to 10 months per TRx.
Q:Have you reached the due diligence stage on any M&A opportunities, and what factors might dissuade you from closing a deal?
A:Vikram Karnani declined to comment on specific opportunities but reiterated the company's balanced capital deployment strategy, which includes business development, share repurchases, and debt repayment. He emphasized that any M&A would align with operational leverage and capital efficiency.
Q:What were the gross to net rates for Nucynta in Q3, and how did rebate settlements impact results?
A:Colleen Tupper reported that the rebate settlement benefit for Nucynta in Q3 was $2.8 million, attributable to first-half activities. Gross to net rates were 28.5% for Nucynta IR and 31.8% for Nucynta ER.
Q:What size of business development transaction would you consider, and are you focused on specific therapeutic areas?
A:Vikram Karnani stated that the company is willing to lever up to 3x net debt over EBITDA, with a current net debt/EBITDA ratio of 1.2, expected to drop below 1x by year-end. The focus is on areas with operational leverage, such as pain and CNS, but they are open to other areas if they are capital-efficient. The priority is on commercial or near-commercial assets.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on M&A opportunities, stating they would not comment on any specific deals in progress. Additionally, they used vague language regarding the potential size and scope of future transactions, emphasizing general strategies rather than concrete plans.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADHD awareness
ADHD prescription
Executive VP
Journal
PM pain
Pain Research
awakening
awareness health
awareness month
balance sheet
care provider
caregiver patient
coverage
date
debt cash
debt repayment
deployment expansion
driver PM
expansion development
force awareness
health care
high
improvement net
indicator
marketing campaign
medicine patient
patient ADHD
payer
poster world
prescription prescribers
prescription school
profitability
repurchase debt
revenue pain
school season
science
segment prescription
COLL Transcript
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 15% revenue increase and improved gross margins. The strategic outlook is optimistic, focusing on future-oriented initiatives. Despite acknowledging risks, the growth in net income and cash flow supports a positive sentiment. Given the small market cap, the stock is likely to react positively within the 2% to 8% range.
Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary and Q&A indicate a positive sentiment. The company reported strong financial performance, with revenue and EBITDA growth, and raised 2025 guidance. Despite increased operational costs, the strategic focus on Jornay PM and share repurchases is promising. The Q&A highlighted stable demand and no significant competitive threats. However, some management responses were vague, slightly tempering enthusiasm. With a market cap of $1.06 billion, the stock is likely to see a positive reaction, between 2% to 8%, given the strong growth and strategic initiatives.
Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript
Positive11-6
The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
COLL Slides
COLL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
